Upside case
Bull case
$140+223.7%
SNY would need investors to value it at roughly 33x earnings — about 23x more generous than today's 10x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated May 1, 2026
Sanofi (SNY) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
27
analysts
14 bullish · 2 bearish · 27 covering SNY
Strong Buy
0
Buy
14
Hold
11
Sell
2
Strong Sell
0
Consensus Target
$50
+15.3% vs today
Scenario Range
$25 – $140
Model bear to bull value window
Coverage
27
Published analyst ratings
Valuation Context
10.3x
Forward P/E · Market cap $104.7B
SNY price targets
Three scenarios for where SNY stock could go
Current
~$43
Confidence
58 / 100
Updated
May 1, 2026
Where we are now
Current · $43
Bear
$25
Base
$69
Bull
$140
Market caseClosest to today
Base case
$69+58.1%
At 16x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$25-42.0%
If investor confidence fades or macro conditions deteriorate, a 4x multiple contraction could push SNY down roughly 42% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Sanofi
SNY · NASDAQHealthcareDrug Manufacturers - GeneralDecember year-end
Sanofi is a global pharmaceutical company that develops and markets prescription drugs, vaccines, and consumer healthcare products. It generates revenue primarily from its Pharmaceuticals segment — including specialty care and diabetes treatments — along with Vaccines and Consumer Healthcare divisions. The company's competitive advantage stems from its diversified portfolio, strong R&D pipeline, and established global commercial infrastructure.
Market Cap
$104.7B
Revenue TTM
$46.7B
Net Income TTM
$7.8B
Net Margin
16.7%
SNY Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
67%Exceptional
12 quarters tracked
Revenue Beat Rate
75%Exceptional
vs consensus estimates
Avg EPS Surprise
-0.2%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 3 of 4Q3 2025
EPS
$0.90/$0.96
Revenue
$12.6B/$12.4B
Q4 2025
EPS
$1.70/$1.60
Revenue
$15.4B/$11.1B
Q1 2026
EPS
$0.89/$0.84
Revenue
$14.3B/$11.7B
Q2 2026
EPS
$1.10/$1.06
Revenue
$12.9B/$12.7B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $0.90/$0.96 | -6.3% | $12.6B/$12.4B | +2.3% |
| Q4 2025 | $1.70/$1.60 | +6.3% | $15.4B/$11.1B | +38.9% |
| Q1 2026 | $0.89/$0.84 | +6.0% | $14.3B/$11.7B | +22.4% |
| Q2 2026 | $1.10/$1.06 | +3.8% | $12.9B/$12.7B | +1.9% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$48.9B
+4.6% YoY
FY2
$51.5B
+5.4% YoY
EPS Outlook
FY1
$3.57
+11.5% YoY
FY2
$3.75
+5.1% YoY
Trailing FCF (TTM)$8.3B
FCF Margin: 17.7%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
SNY beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
SNY Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $57.1B
Product Mix
Latest annual revenue by segment or product family
Segment breakdown not available for this company.
Geographic Mix
Latest annual revenue by reported region
Reportable Geographical Zones
76.4%
+1.3% YoY
Tap, hover, or focus a slice to inspect segment detail.
Reportable Geographical Zones is the largest reported region at 76.4%, up 1.3% YoY.
SNY Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Slightly Undervalued
Fair value est. $53 — implies +14.8% from today's price.
Upside to Fair Value
14.8%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
SNY
18.2x
vs
S&P 500
25.1x
28% discount
vs Healthcare Trailing P/E
SNY
18.2x
vs
Healthcare
22.2x
18% discount
vs SNY 5Y Avg P/E
Today
18.2x
vs
5Y Average
20.9x
13% discount
Forward PE
10.3x
S&P 500
19.1x
-46%
Healthcare
18.8x
-45%
5Y Avg
—
—
Trailing PE
18.2x
S&P 500
25.1x
-28%
Healthcare
22.2x
-18%
5Y Avg
20.9x
-13%
PEG Ratio
—
S&P 500
1.72x
—
Healthcare
1.53x
—
5Y Avg
—
—
EV/EBITDA
10.8x
S&P 500
15.2x
-29%
Healthcare
14.0x
-23%
5Y Avg
11.9x
-9%
Price/FCF
10.0x
S&P 500
21.1x
-52%
Healthcare
18.6x
-46%
5Y Avg
15.5x
-35%
Price/Sales
1.9x
S&P 500
3.1x
-39%
Healthcare
2.8x
-32%
5Y Avg
2.9x
-34%
Dividend Yield
5.08%
S&P 500
1.87%
+172%
Healthcare
1.42%
+257%
5Y Avg
3.59%
+41%
| Metric | SNY | S&P 500 | Healthcare | 5Y Avg SNY |
|---|---|---|---|---|
| Forward PE | 10.3x | 19.1x-46% | 18.8x-45% | — |
| Trailing PE | 18.2x | 25.1x-28% | 22.2x-18% | 20.9x-13% |
| PEG Ratio | — | 1.72x | 1.53x | — |
| EV/EBITDA | 10.8x | 15.2x-29% | 14.0x-23% | 11.9x |
| Price/FCF | 10.0x | 21.1x-52% | 18.6x-46% | 15.5x-35% |
| Price/Sales | 1.9x | 3.1x-39% | 2.8x-32% | 2.9x-34% |
| Dividend Yield | 5.08% | 1.87% | 1.42% | 3.59% |
SNY trades above S&P 500 benchmarks on 0 of 5 measured multiples — appears modestly priced relative to the S&P 500 on most measures.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolSNY Financial Health
Verdict
Strong
SNY generates $8.3B in free cash flow at a 17.7% margin — returns 10.5% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$46.7B
Revenue Growth
TTM vs prior year
+14.1%
Gross Margin
Gross profit as a share of revenue
72.3%
Operating Margin
Operating income divided by revenue
13.6%
Net Margin
Net income divided by revenue
16.7%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$3.20
Free Cash Flow (TTM)
Cash generation after capex
$8.3B
FCF Margin
FCF as share of revenue — the primary cash quality signal
17.7%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
5.5%
ROA
Return on assets, trailing twelve months
6.1%
Cash & Equivalents
Liquid assets on the balance sheet
$7.7B
Net Debt
Total debt minus cash
$14.1B
Debt Serviceability
Net debt as a multiple of annual free cash flow
1.7× FCF
~1.7 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
10.8%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
10.5%
Dividend
5.1%
Buyback
5.4%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$4.8B
Dividend / Share
Annualized trailing dividend per share
$1.88
Payout Ratio
Share of earnings distributed as dividends
58.7%
Shares Outstanding
Declining as buybacks retire shares
2.4B
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageSNY Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 11, 2026
High Risk
Regulatory & Liability
Sanofi faces 7 major legal risks, including evolving global pharmaceutical regulations, lengthy marketing authorisation processes, and potential product liability claims. These can delay product launches and increase compliance costs, threatening revenue streams.
High Risk
Manufacturing & Supply Chain
Sanofi's complex manufacturing processes are subject to strict standards; production delays, contamination remediation, or recalls can lead to significant expenses, lost sales, and delayed launches. Epidemic outbreaks further heighten disruption risk.
High Risk
Revenue Concentration
Dupixent accounted for 36.0% of Sanofi's net sales in 2025, making the company highly sensitive to safety, reimbursement, or competitive challenges affecting this single product. A decline could materially reduce overall cash flows.
Medium
Pricing & Reimbursement
Sanofi faces increasing cost‑containment pressures and policy changes such as the Inflation Reduction Act and MFN agreements, especially in the U.S., which could lower net prices and reimbursement rates, compressing margins.
Medium
R&D & Pipeline
Sanofi invests 18.0% of net sales in R&D, yet past failures and a limited number of pipeline triggers raise the risk that new products may not materialise, jeopardising portfolio renewal and future growth.
Lower
Geopolitical & Macro
Global operations expose Sanofi to deteriorating diplomatic relations, climate‑change impacts, and macro‑economic volatility, which could disrupt supply chains, increase costs, or limit market access.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why SNY Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 11, 2026
Robust Financial Growth & Cash Flow
Sanofi has delivered consistent profitability and positive operating cash flow for the past five years, underscoring its financial resilience. Earnings forecasts project a significant increase in EPS, while revenue growth is expected to continue at a moderate pace.
Promising Pipeline: Amlitelimab & Lunsekimig
The company secured positive Phase 3 results for amlitelimab in atopic dermatitis, a first‑in‑class therapy with strong market potential. Additionally, Phase 2 data for lunsekimig in respiratory studies signal further revenue opportunities.
Attractive Dividend Yield & Sustainability
Sanofi offers a meaningful dividend yield that appeals to income‑focused investors. Its dividend payout ratio is considered sustainable, supporting ongoing shareholder returns.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
SNY Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$43.36
52W Range Position
2%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$43.09
+0.6% from the low
52-Week High
$54.75
-20.8% from the high
1 Month
-8.91%
3 Month
-8.70%
YTD
-10.1%
1 Year
-20.6%
3Y CAGR
-8.0%
5Y CAGR
-3.0%
10Y CAGR
+1.0%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
SNY vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
10.3x
vs 10.4x median
-1% below peer median
Revenue Growth
+4.6%
vs +8.1% median
-42% below peer median
Net Margin
16.7%
vs 19.2% median
-13% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
SNY SNY Sanofi | $104.7B | 10.3x | +4.6% | 16.7% | Buy | +15.3% |
NVO NVO Novo Nordisk A/S | $151.4B | 2.1x | +8.1% | 33.1% | Buy | +4.7% |
AZN AZN AstraZeneca PLC | $281.0B | 17.6x | +9.5% | 17.2% | Buy | +16.4% |
NVS NVS Novartis AG | $277.6B | 16.6x | +5.0% | 24.1% | Hold | -3.1% |
GSK GSK GSK plc | $101.3B | 10.4x | +9.2% | 19.2% | Hold | +4.1% |
PFE PFE Pfizer Inc. | $150.4B | 8.9x | -2.7% | 11.8% | Hold | +3.1% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
SNY Dividend and Capital Return
SNY returns 10.5% annually — 5.08% through dividends and 5.4% through buybacks.
Dividend SustainableFCF Adequate
Total Shareholder Yield
10.5%
Dividend + buyback return per year
Buyback Yield
5.4%
Dividend Yield
5.08%
Payout Ratio
58.7%
How SNY Splits Its Return
Div 5.08%
Buyback 5.4%
Dividend 5.08%Buybacks 5.4%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$1.88
Growth Streak
Consecutive years of dividend increases
2Y
3Y Div CAGR
2.4%
5Y Div CAGR
4.6%
Ex-Dividend Date
—
Payment Cadence
Semi-Annual
2 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$4.8B
Estimated Shares Retired
111M
Approx. Share Reduction
4.6%
Shares Outstanding
Current diluted share count from the screening snapshot
2.4B
At 4.6%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $1.77 | — | — | — |
| 2025 | $2.20 | +7.8% | 4.1% | 8.0% |
| 2024 | $2.04 | +7.0% | 0.3% | 4.1% |
| 2023 | $1.90 | -6.9% | 0.5% | 4.0% |
| 2022 | $2.04 | +7.2% | 0.4% | 3.8% |
FAQ
7 questionsSNY Investor Questions
Common questions answered from live analyst data and company financials.
01Is Sanofi (SNY) stock a buy or sell in 2026?
Sanofi (SNY) is rated Buy by Wall Street analysts as of 2026. Of 27 analysts covering the stock, 14 rate it Buy or Strong Buy, 11 rate it Hold, and 2 rate it Sell or Strong Sell. The consensus 12-month price target is $50, implying +15.3% from the current price of $43. The bear case scenario is $25 and the bull case is $140.
02What is the SNY stock price target for 2026?
The Wall Street consensus price target for SNY is $50 based on 27 analyst estimates. The high-end target is $50 (+15.3% from today), and the low-end target is $50 (+15.3%). The base case model target is $69.
03Is Sanofi (SNY) stock overvalued in 2026?
SNY trades at 10.3x times forward earnings. The stock currently trades at a discount to the broader market. Based on current multiples versus the peer group, the relative model signals slightly undervalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Sanofi (SNY) stock in 2026?
The primary risks for SNY in 2026 are: (1) Regulatory & Liability — Sanofi faces 7 major legal risks, including evolving global pharmaceutical regulations, lengthy marketing authorisation processes, and potential product liability claims. (2) Manufacturing & Supply Chain — Sanofi's complex manufacturing processes are subject to strict standards; production delays, contamination remediation, or recalls can lead to significant expenses, lost sales, and delayed launches. (3) Revenue Concentration — Dupixent accounted for 36. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Sanofi's revenue and earnings forecast?
Analyst consensus estimates SNY will report consensus revenue of $48.9B (+4.6% year-over-year) and EPS of $3.57 (+11.5% year-over-year) for the upcoming fiscal year. The following year, analysts project $51.5B in revenue.
06When does Sanofi (SNY) report its next earnings?
A confirmed upcoming earnings date for SNY is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does Sanofi generate?
Sanofi (SNY) generated $8.3B in free cash flow over the trailing twelve months — a free cash flow margin of 17.7%. SNY returns capital to shareholders through dividends (5.1% yield) and share repurchases ($4.8B TTM).